Patents by Inventor Surya K. Goli
Surya K. Goli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20020012983Abstract: The present invention provides four NADH dehydrogenase subunits (designated individually as NDS-1, NDS-2, NDS-3, and NDS-4 and collectively as NDS) and polynucleotides which identify and encode NDS. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NDS and a method for producing NDS. The invention also provides for use of NDS and agonists, antibodies, or antagonists specifically binding NDS, in the prevention and treatment of diseases associated with expression of NDS. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NDS for the treatment of diseases associated with the expression of NDS. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NDS.Type: ApplicationFiled: September 10, 1998Publication date: January 31, 2002Inventors: OLGA BANDMAN, SURYA K. GOLI, JENNIFER L. HILLMAN
-
Publication number: 20020001827Abstract: The present invention provides novel human cytokines (designated individually as NHC-1 and NHC-2, and collectively as NHC) and polynucleotides which identify and encode NHC. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NHC and a method for producing NHC. The invention also provides for use of NHC and agonists, antibodies, or antagonists specifically binding NHC, in the prevention and treatment of diseases associated with expression of NHC. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NHC for the treatment of diseases associated with the expression of NHC. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NHC.Type: ApplicationFiled: February 12, 2001Publication date: January 3, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Phillip R. Hawkins, Lynn E. Murry, Surya K. Goli
-
Publication number: 20010041356Abstract: The present invention provides four NADH dehydrogenase subunits (designated individually as NDS-1, NDS-2, NDS-3, and NDS-4 and collectively as NDS) and polynucleotides which identify and encode NDS. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NDS and a method for producing NDS. The invention also provides for use of NDS and agonists, antibodies, or antagonists specifically binding NDS, in the prevention and treatment of diseases associated with expression of NDS. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NDS for the treatment of diseases associated with the expression of NDS. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NDS.Type: ApplicationFiled: November 29, 2000Publication date: November 15, 2001Applicant: Incyte Pharmaceuticals, IncInventors: Olga Bandman, Surya K. Goli, Jennifer L. Hillman
-
Patent number: 6307021Abstract: The present invention provides a human apoptosis regulator protein (APRG) and polynucleotides which identify and encode APRG. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding APRG and a method for producing APRG. The invention also provides for agonists, antibodies, or antagonists specifically binding APRG, and their use, in the prevention and treatment of diseases associated with expression of APRG. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding APRG for the treatment of diseases associated with the expression of APRG. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding APRG.Type: GrantFiled: November 24, 1998Date of Patent: October 23, 2001Assignee: Incyte Genomics, Inc.Inventors: Olga Bandman, Surya K. Goli, Jennifer L. Hillman
-
Patent number: 6303297Abstract: The present invention is a computerized storage and retrieval system for genetic information and related annotated information. The data of the system is stored in a relational database which interfaces with public databases to allow analysis both within the database of the invention and between information within that database and external public databases. The sequence data is edited before entry into the system, and is stored in a curated, functional clustering organization. The information associated with the data is stored in an expression database that is linked to the storage of the sequence data.Type: GrantFiled: November 13, 1997Date of Patent: October 16, 2001Assignee: Incyte Pharmaceuticals, Inc.Inventors: Steve E. Lincoln, Tod M. Klingler, Janice Au-Young, Y. Tom Tang, Richard D. Goold, Ingrid E. Akerblom, Jeffrey J. Seilhamer, Phillip R. Hawkins, Lynn E. Murry, Angelo M. Delegeane, Wendy B. Levine, Jennifer L. Hillman, Surya K. Goli, Christina M. Altus, Olga Bandman, Samuel T. LaBrie, Purvi Shah
-
Patent number: 6281190Abstract: The present invention provides a human LEA motif protein (HuLEAP) and polynucleotides which identify and encode HuLEAP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HuLEAP and a method for producing HuLEAP. The invention also provides for agonists, antibodies, or antagonists specifically binding HuLEAP, and their use, in the prevention and treatment of diseases associated with expression of HuLEAP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HuLEAP for the treatment of diseases associated with the expression of HuLEAP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HuLEAP.Type: GrantFiled: December 15, 1998Date of Patent: August 28, 2001Assignee: Incyte Genomics, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 6280733Abstract: The present invention provides a human microtubule-associated protein (hLC3) and the polynucleotides which identify and encode hLC3. The invention also provides genetically engineered expression vectors, host cells, and a method for producing hLC3. The invention also provides hLC3 as well as agonists, antibodies, and antagonists of hLC3, and the use thereof for the prevention and treatment of diseases associated with the expression of hLC3. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding hLC3 for the treatment of diseases associated with the expression of hLC3. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding hLC3.Type: GrantFiled: November 24, 1998Date of Patent: August 28, 2001Assignee: Incyte Genomics, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Publication number: 20010012831Abstract: The present invention provides a human calcium-binding protein (HCBP) and polynucleotides which identify and encode HCBP. The invention also provides expression vectors and host cells, agonists, antibodies, and antagonists. In addition, the invention provides methods for producing HCBP and for treating or preventing disorders associated with the expression of HCBP.Type: ApplicationFiled: January 23, 2001Publication date: August 9, 2001Applicant: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 6248325Abstract: The present invention provides a human glutathione s-transferase (HGST) and polynucleotides which identify and encode HGST. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HGST and a method for producing HGST. The invention also provides for agonists, antibodies, or antagonists specifically binding HGST, and their use, in the prevention and treatment of cancer and other diseases associated with the expression of HGST. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HGST for the treatment of cancer and other diseases associated with the expression of HGST. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HGST.Type: GrantFiled: May 11, 1999Date of Patent: June 19, 2001Assignee: Incyte GenomicsInventors: Surya K. Goli, Jennifer L. Hillman
-
Patent number: 6228616Abstract: The present invention provides a novel human anion channel (NANCH) and polynucleotides which identify and encode NANCH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NANCH and a method for producing NANCH. The invention also provides for agonists, antibodies, or antagonists specifically binding NANCH, and their use, in the prevention and treatment of diseases associated with expression of NANCH. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NANCH for the treatment of diseases associated with the expression of NANCH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NANCH.Type: GrantFiled: November 19, 1999Date of Patent: May 8, 2001Assignee: Incyte Genomics, Inc.Inventors: Olga Bandman, Surya K. Goli
-
Patent number: 6207148Abstract: The invention provides human disease associated protein kinases and polynucleotides (collectively designated DAPK) which identify and encode them. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention further provides methods for diagnosing and treating disorders associated with expression of human disease associated protein kinases.Type: GrantFiled: March 19, 1999Date of Patent: March 27, 2001Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Jennifer L. Hillman, Neil C. Corley, Karl J. Guegler, Preeti Lal, Surya K. Goli, Purvi Shah
-
Patent number: 6204021Abstract: The present invention provides novel human cytokines (designated individually as NHC-1 and NHC-2, and collectively as NHC) and polynucleotides which identify and encode NHC. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NHC and a method for producing NHC. The invention also provides for use of NHC and agonists, antibodies, or antagonists specifically binding NHC, in the prevention and treatment of diseases associated with expression of NHC. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NHC for the treatment of diseases associated with the expression of NHC. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NHC.Type: GrantFiled: January 31, 1997Date of Patent: March 20, 2001Assignee: Incyte Genomics, Inc.Inventors: Olga Bandman, Phillip R. Hawkins, Lynn E. Murry, Surya K. Goli
-
Patent number: 6194385Abstract: The present invention provides a human calcium-binding protein (HCBP) and polynucleotides which identify and encode HCBP. The invention also provides expression vectors and host cells, agonists, antibodies, and antagonists. In addition, the invention provides methods for producing HCBP and for treating or preventing disorders associated with the expression of HCBP.Type: GrantFiled: December 7, 1998Date of Patent: February 27, 2001Assignee: Incyte Genomics, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 6184357Abstract: The present invention provides a human prostate-specific kallikrein (HPSK) and polynucleotides which identify and encode HPSK. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPSK and a method for producing HPSK. The invention also provides for agonists, antibodies, or antagonists specifically binding HPSK, and their use, in the prevention and treatment of diseases associated with the expression of HPSK. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPSK for the treatment of diseases associated with the expression of HPSK. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPSK.Type: GrantFiled: March 3, 1999Date of Patent: February 6, 2001Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli
-
Patent number: 6172199Abstract: The present invention provides a polynucleotide (ubcp) which identifies and encodes a novel ubiquitin-conjugating enzyme (UBCP). The invention provides for genetically engineered expression vectors and host cells comprising the nuclei acid sequence encoding UBCP. The invention also provides for the use of substantially purified UBCP and its agonists, antagonists, or inhibitors in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of UBCP. Additionally, the invention provides for the use of antisense molecules to ubcp in pharmaceutical compositions for treatment of diseases associated with the expression of UBCP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of ubcp or anti-UBCP antibodies which specifically bind to UBCP.Type: GrantFiled: May 25, 1999Date of Patent: January 9, 2001Assignee: Incyte Pharmaceuticals, Inc.Inventors: Janice Au-Young, Surya K. Goli, Jennifer L. Hillman
-
Patent number: 6156523Abstract: The invention provides human serine/threonine protein kinases (HSTK) and polynucleotides which identify and encode HSTK. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of HSTK.Type: GrantFiled: September 16, 1998Date of Patent: December 5, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Y. Tom Tang, Surya K. Goli, Neil C. Corley, Karl J. Guegler, Gina A. Gorgone, Jennifer L. Hillman
-
Patent number: 6136314Abstract: The present invention provides a human histone fusion protein (HFP) and polynucleotides which identify and encode HFP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention also provides methods for producing HFP and for treating or preventing disorders associated with expression of HFP.Type: GrantFiled: July 14, 1999Date of Patent: October 24, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 6130325Abstract: The present invention provides two human p24 vesicle trafficking proteins (designated individually as Hp24-1 and Hp24-2 and collectively as Hp24) and polynucleotides which identify and encode Hp24. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding Hp24 and a method for producing Hp24. The invention also provides for agonists, antibodies, or antagonists specifically binding Hp24, and their use, in the prevention and treatment of diseases associated with expression of Hp24. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding Hp24 for the treatment of diseases associated with the expression of Hp24. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding Hp24.Type: GrantFiled: February 14, 1997Date of Patent: October 10, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Surya K. Goli, Olga Bandman
-
Patent number: 6124123Abstract: The present invention provides a human ubiquitin-conjugating enzyme (UBCPB) and polynucleotides which identify and encode UBCPB. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding UBCPB and a method for producing UBCPB. The invention also provides for agonists, antibodies, or antagonists specifically binding UBCPB, and their use, in the prevention and treatment of diseases associated with expression of UBCPB. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding UBCPB for the treatment of diseases associated with the expression of UBCPB. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding UBCPB.Type: GrantFiled: August 12, 1998Date of Patent: September 26, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli
-
Patent number: 6110686Abstract: The present invention provides a human cystatin-like protein (CSTIN) and polynucleotides which identify and encode CSTIN. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding CSTIN and a method for producing CSTIN. The invention also provides for agonists, antibodies, or antagonists specifically binding CSTIN, and their use, in the prevention and treatment of diseases associated with expression of CSTIN. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding CSTIN for the treatment of diseases associated with the expression of CSTIN. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding CSTIN.Type: GrantFiled: May 19, 1999Date of Patent: August 29, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli